SillaJen, ABL expand deal to ready vaccine for clinic

SillaJen Inc. (KOSDAQ:215600) and the ABL Europe unit of Institut Mérieux (Lyon, France) added oncolytic virus JX-970 to a 2016 manufacturing deal under which ABL is manufacturing Pexa-Vac. The company expects to bring JX-970 into clinical trials next half. SillaJen declined to disclose financial terms...